Dr. Bing serves as the Co-founder, Chairman and CEO of D2M Biotherapeutics. Driven by his 20 years of experiences and insights in applying genetics data for targets and therapeutics development, Dr. Bing co-founded D2M in 2020.
Prior to D2M, Dr. Bing served as Senior Director, Human Genetics & Target Science at Pfizer. Under his leadership, Dr. Bing’s genetics team played critical scientific and strategic roles in Pfizer’s immune & inflammation R&D program assessment and evaluation. His group provided important decision-making contributions on several high-profile assets currently in clinic development at Pfizer. Before his tenure at Pfizer, Dr. Bing served as Investigator and Principal Scientist in Genetics Research group at GlaxoSmithKline.
Dr. Bing holds his Ph.D of Genetics and Bioinformatics from Virginia Tech, and M.D. from China Medical University.